hemophilia

Sigilon picks up $80M to test hemophilia cell therapy in humans
Sigilon picks up $80M to test hemophilia cell therapy in humans
Fierce Biotech
Siglion Therapeutics
cell terhapy
hemophilia
Flag link:
Novo Nordisk Pauses 3 Clinical Trials Testing Hemophilia Therapy
Novo Nordisk Pauses 3 Clinical Trials Testing Hemophilia Therapy
Xconomy
Novo Nordisk
clinical trials
concizumab
hemophilia
Flag link:
BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy
BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy
Motley Fool
Biomarin
JPMHC 2020
drug pricing
valrox
hemophilia
Flag link:
BioMarin sets gene therapy sights beyond hemophilia
BioMarin sets gene therapy sights beyond hemophilia
BioPharma Dive
Biomarin
hemophilia
gene therapy
Flag link:
Value-based pricing for gene therapy? Maybe not ready for hemophilia
Value-based pricing for gene therapy? Maybe not ready for hemophilia
Biopharma Dive
Biomarin
hemophilia
hemophilia A
gene therapy
valoctocogene roxaparvovec
uniQure
hemophilia B
etranadez
Flag link:
Sangamo keeps pressure on rivals with updated hemophilia data
Sangamo keeps pressure on rivals with updated hemophilia data
Biopharma Dive
ASH2019
Pfizer
Sangamo
hemophilia
SB-525
Flag link:
Why Novo Nordisk should buy Uniqure
Why Novo Nordisk should buy Uniqure
EP Vantage
Novo Nordisk
gene editing
hemophilia
uniQure
Bluebird Bio
Flag link:
The return of Vioxx: Can a drug once deemed deadly be relaunched to treat rare disease?
The return of Vioxx: Can a drug once deemed deadly be relaunched to treat rare disease?
Stat
Vioxx
hemophilia
generics
Tremeau Pharmaceuticals
hemophilic arthropathy
Flag link:
Novo taps bluebird bio for gene-editing tech
Novo taps bluebird bio for gene-editing tech
Fierce Biotech
Novo Nordisk
Bluebird Bio
R&D
gene editing
hemophilia
Flag link:
BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end
BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end
Fierce Biotech
Biomarin
hemophilia
gene therapy
valoctocogene roxaparvovec
valrox
hemophilia A
Flag link:
Thrashed by a 'surprise' rival, Sanofi writes off $2B on soured hemophilia deal
Thrashed by a 'surprise' rival, Sanofi writes off $2B on soured hemophilia deal
Endpoints
Sanofi
earnings
Roche
Hemlibra
hemophilia
Eloctate
Flag link:
Pharmacquired: Is $11B enough to secure Sanofi's spot in hemophilia?
Pharmacquired: Is $11B enough to secure Sanofi's spot in hemophilia?
Biopharma Dive
Sanofi
M&A
Bioverativ
hemophilia
gene therapy
Flag link:
Sangamo Stock Soars on Positive Hemophilia Treatment Trial
Sangamo Stock Soars on Positive Hemophilia Treatment Trial
TheStreet.com
Sangamo BioSciences
Pfizer
SB-525
hemophilia
clinical trials
Flag link:
IP trouble defers launch of Novo's long-acting hemophilia therapy
IP trouble defers launch of Novo's long-acting hemophilia therapy
Endpoints
Novo Nordisk
Eseproct
hemophilia
Roche
Hemlibra
Flag link:
FDA hemophilia meeting to discuss new efficacy endpoints
FDA hemophilia meeting to discuss new efficacy endpoints
BioCentury
FDA
clinical trials
hemophilia
Flag link:
Genentech and Hemophilia Patients Eye Oct. 4 for Hemlibra Ruling
Genentech and Hemophilia Patients Eye Oct. 4 for Hemlibra Ruling
BioSpace
FDA
Genentech
Hemlibra
hemophilia
Flag link:
Catalyst gives positive hemophilia update as 2 more subjects complete study
Catalyst gives positive hemophilia update as 2 more subjects complete study
Biopharma Dive
Catalyst Bioscences
hemophilia
clinical trials
Flag link:
What's Next for Spark Therapeutics
What's Next for Spark Therapeutics
Motley Fool
Spark Therapeutics
hemophilia
SPK-8011
Flag link:
A bad week for these two biotechs
A bad week for these two biotechs
Motley Fool
Anika Therapeutics
CINGAL
Catalyst Biosciences
CB 2679d
hemophilia
Flag link:
FDA plans to speed path to approval for some gene therapies, starting with hemophilia
FDA plans to speed path to approval for some gene therapies, starting with hemophilia
Stat
FDA
drug approvals
gene therapies
Scott Gottlieb
hemophilia
Flag link:

Pages